{"id":593378,"date":"2022-03-28T18:36:02","date_gmt":"2022-03-28T18:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=593378"},"modified":"2022-03-28T18:36:02","modified_gmt":"2022-03-28T18:36:02","slug":"primary-biliary-cholangitis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-estimates-delveinsight-key-companies-genfit-zydus-cadila-genkyotex-and-cymabay-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/primary-biliary-cholangitis-market-is-predicted-to-exhibit-remarkable-growth-by-2032-estimates-delveinsight-key-companies-genfit-zydus-cadila-genkyotex-and-cymabay-therapeutics_593378.html","title":{"rendered":"Primary Biliary Cholangitis Market is Predicted to Exhibit Remarkable Growth by 2032, Estimates DelveInsight | Key Companies – Genfit, Zydus Cadila, Genkyotex, and CymaBay Therapeutics"},"content":{"rendered":"
\n
\"Primary<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Primary Biliary Cholangitis market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. <\/p>\n

\"Primary<\/p>\n

Primary Biliary Cholangitis: An Overview<\/strong><\/p>\n

Primary biliary cirrhosis (PBC), now known as primary biliary cholangitis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts resulting in periportal inflammation, cholestasis. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension.<\/em><\/p>\n

Primary biliary cirrhosis is the most common cholestatic disease of middle-aged women in the United States. Researchers theorize that patient with PBC has both genetic predisposition with the right environmental trigger. The prevalence of the disease is 100-fold higher in first-degree relatives of the index patient, which strongly suggests a genetic predisposition.<\/em><\/p>\n

Primary Biliary Cholangitis Market Key Facts<\/strong><\/p>\n